| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | NaN | NaN | NaN | 0 |
| Research and development | 5,207,564 | 7,589,797 | 3,521,576 | 3,507,906 |
| General and administrative | 518,190 | 355,194 | 653,066 | 538,047 |
| Total operating expenses | 5,725,754 | 7,944,991 | 4,174,642 | 4,045,953 |
| Loss from operations | -5,725,754 | -7,944,991 | -4,174,642 | -4,045,953 |
| Interest income | 68,617 | 22,258 | 22,797 | 20,675 |
| Net loss | -5,657,137 | -7,922,733 | -4,151,845 | -4,025,278 |
| Basic EPS | -0.39 | -0.568 | -0.3 | -0.3 |
| Diluted EPS | -0.39 | -0.568 | -0.3 | -0.3 |
| Basic Average Shares | 14,565,230 | 13,956,054 | 13,641,384 | 13,370,983 |
| Diluted Average Shares | 14,565,230 | 13,956,054 | 13,641,384 | 13,370,983 |
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)